SynthesisMedicine2015
The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Synthesis in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 5 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Assessment of Prognostic Value of Aspartate Aminotransferase-to-Platelet Ratio Index in Patients With Hepatocellular Carcinoma: Meta-Analysis of 28 Cohort Studies.Frontiers in medicine · 2021Pooled it
- Prognostic role of pretreatment thrombocytosis on survival in patients with cervical cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2019Pooled it
- Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis.BMC cancer · 2019Pooled it
- FIB-4 index serves as a noninvasive prognostic biomarker in patients with hepatocellular carcinoma: A meta-analysis.Medicine · 2018Pooled it
- Pooled it
- Systemic hematologic, metabolic, and inflammatory dysregulation in liver cirrhosis and hepatocellular carcinoma: diagnostic utility of novel indices in an Egyptian cohort.BMC gastroenterology · 2026Article
- Multiphasic CT-based multimodal deep learning model for predicting early hepatocellular carcinoma recurrence following liver transplantation.Frontiers in oncology · 2026Article
- Development and Validation of an Interpretable Machine Learning Model for Predicting Tumor Recurrence After Microwave Ablation in Small Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Prognostic value of the three-lineage cytopenia score in locally advanced nasopharyngeal carcinoma: A retrospective cohort study.PloS one · 2026Article
- Explainable machine learning model for predicting the transarterial chemoembolization response and subtypes of hepatocellular carcinoma patients.BMC gastroenterology · 2025Article
- Liver resection in stage 0-A HCC in segments 7/8: a propensity-matched analysis comparing open, laparoscopic, and robotic approach.Surgical endoscopy · 2025Article
- Development and clinical validation of a novel platelet count-based nomogram for predicting microvascular invasion in HCC.Scientific reports · 2025Article
- Prognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis.Journal of hepatocellular carcinoma · 2025Article
- Long-Term Analysis of Recurrence Beyond Milan Criteria Following Ablation of Solitary Early-Stage Hepatocellular Carcinoma ≤3 cm in Potentially Transplantable Patients: A Over 10-Year Survival Study.Journal of hepatocellular carcinoma · 2025Article
- Article
- Impact of Thrombocytopenia on Survival in Patients with Hepatocellular Carcinoma: Updated Meta-Analysis and Systematic Review.Cancers · 2024Review
- Survival analysis of patients with hepatocellular carcinoma based on the ratio of platelet count to spleen diameter.Frontiers in pharmacology · 2024Article
- Ensemble learning enhances the precision of preliminary detection of primary hepatocellular carcinoma based on serological and demographic indices.Frontiers in oncology · 2024Article
- Hepatocellular Carcinoma: Surgical Management and Evolving Therapies.Cancer treatment and research · 2024Review
- New and Old Key Players in Liver Cancer.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombocytopenia has been acknowledged to be a crucial risk factor for cirrhosis formation and hepatocarcinogenesis in chronic liver diseases. However, to date, the association between platelet count (PLT) and the prognosis of hepatocellular carcinoma (HCC) remains inconsistent and controversial. The aim of the present study was to determine whether PLT could be used as a useful predictor of survival in patients with HCC. We performed systematic review in online databases, including PubMed, EmBase, and Web of Science, from inception until 2014. Studies were included if a statistical relationship was investigated between PLT and survival for HCC, and hazard ratio (HR) and 95% confidence intervals (CIs) for overall survival (OS) or recurrence-free survival (RFS) were provided. The quality of each included study was assessed by Newcastle-Ottawa scale score. To synthesize these studies, a random-effects model or a fixed-effects model was applied as appropriate. Then, we calculated heterogeneity, performed sensitivity analysis, tested publication bias, and did subgrouped and meta-regression analysis. Finally, we identified 33 eligible articles (published from 1998 to 2014) involved 5545 patients by retrieval. A low level of preoperative PLT was found to be significantly associated with a poor survival of HCC. Irrespective of the therapy used, the pooled HRs for OS and RFS were 1.41 (95% CI, 1.14-1.75) and 1.44 (95% CI, 1.13-1.83), respectively. Specifically, in patients who underwent liver resection, the pooled HRs for OS and RFS were 1.67 (95% CI, 1.22-2.27) and 1.44 (95% CI, 1.04-1.99), respectively. Furthermore, patients with preoperative thrombocytopenia (PLT < 100 × 10⁹/L) had a worse OS (HR: 1.73, 95% CI, 1.29-2.32) and RFS (HR: 1.57, 95% CI, 1.31-1.87) in comparison with patients without thrombocytopenia. All our findings showed no significant changes due to the removal of any study or the use of an opposite-effects model, and there was no significant publication bias. The limitations of this meat-analysis were nonuniform cut-off values of PLT, high between-study heterogeneities, potential confounders, and a bias of publication year. A low preoperative PLT level results in an unfavorable outcome in HCC. PLT is a simple, inexpensive, and useful predictor of survival in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.